Document Detail

General strategy for the management of bronchial asthma in pregnancy.
MedLine Citation:
PMID:  12854627     Owner:  NLM     Status:  MEDLINE    
Epidemiological studies showed that bronchial asthma is one of the most common diseases which can complicate pregnancy (1-7%). In about 0.05-2% of the cases, asthma occurs as a life-threatening event. In the common medical practice a waiting strategy or, even, the complete refusal for drug therapies are frequently observed. This is justified by the fear of the possible adverse effects of drugs on developing fetus. On the contrary, several studies have demonstrated that severe and uncontrolled asthma may produce serious maternal and fetal complications, such as gestational hypertension and eclampsia, fetal hypoxemia and an increased risk of perinatal death. Therefore, all pregnant women suffering from bronchial asthma should be considered as potentially at high risk of complications and adequately treated. Since asthma is a chronic disease with acute exacerbations, a continuous treatment is mandatory to control symptoms, to prevent acute episodes and to reduce the degree of airway inflammation. The global strategy for asthma management in pregnancy includes five main topics: (1) objective evaluation of maternal/ fetal clinical conditions; (2) avoidance/control of triggering factors; (3) pharmacological treatment; (4) educational support; (5) psychological support. As far as drug therapy is concerned, the International Guidelines and Recommendations suggest that the general strategy does not differ significantly from management outside pregnancy. We herein review and discuss the available data and the criteria for the management of asthma in pregnant patients.
G Liccardi; M Cazzola; G W Canonica; M D'Amato; G D'Amato; G Passalacqua
Related Documents :
9298717 - Asthma in pregnancy.
12535577 - Efflux transporters of the human placenta.
15035567 - Treatment of allergic rhinitis during pregnancy.
6588957 - The outcome of pregnancies complicated by narcotic drug addiction.
8169907 - Proper selection of patients for intermediate-dose pure follicle stimulating hormone.
18318867 - Abortion in the united states: incidence and access to services, 2005.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Respiratory medicine     Volume:  97     ISSN:  0954-6111     ISO Abbreviation:  Respir Med     Publication Date:  2003 Jul 
Date Detail:
Created Date:  2003-07-11     Completed Date:  2003-08-04     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8908438     Medline TA:  Respir Med     Country:  England    
Other Details:
Languages:  eng     Pagination:  778-89     Citation Subset:  IM    
Unit of Pneumology and Allergology, Department of Chest Diseases, A.Cardarelli Hospital, Piazza Arenella no 7/h, Naples 80128, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adrenergic beta-Agonists / therapeutic use*
Androstadienes / contraindications
Anesthesia, Local
Anesthesia, Obstetrical
Asthma / drug therapy*,  psychology,  therapy
Bronchodilator Agents / therapeutic use*
Chronic Disease
Cromolyn Sodium / therapeutic use
Glucocorticoids / therapeutic use
Histamine H1 Antagonists / therapeutic use
Obstetric Labor Complications / drug therapy
Oxytocics / contraindications
Patient Education as Topic
Pregnancy Complications / drug therapy*,  psychology,  therapy
Theophylline / adverse effects,  therapeutic use
Reg. No./Substance:
0/Adrenergic beta-Agonists; 0/Androstadienes; 0/Bronchodilator Agents; 0/Glucocorticoids; 0/Histamine H1 Antagonists; 0/Oxytocics; 15826-37-6/Cromolyn Sodium; 58-55-9/Theophylline; 90566-53-3/fluticasone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Bacterial infections in patients requiring admission for an acute exacerbation of COPD; a 1-year pro...
Next Document:  Use of endoscopic fibrinogen-thrombin in the treatment of severe hemoptysis.